Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant imiquimod to reduce recurrence after surgery for anal HPV lesions
2017-000842-23Phase 3Terminated
- Sponsor
- Medical University of Innsbruck
- Start
- Jan 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anal human papillomavirus infection, anal intraepithelial neoplasia (AIN) and anal human papillomavirus lesion comparing Adjuvant imiquimod (Aldara) with Placebo (2 arms). Primary endpoint: Regression rate within 12 months after fulguration. Started Jan 2018; status: terminated.
02
Drugs
imiquimod
03
Conditions
anal human papillomavirus infectionanal intraepithelial neoplasia (AIN)anal human papillomavirus lesion
Beyond the preview
Go deeper on 2017-000842-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000842-23.